Global Short Bowel Syndrome Market - Analysis, Size, Share, Growth, Trends & Forecast to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Short Bowel Syndrome Market, Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Short Bowel Syndrome Market - Scope of the Report

This report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983-2015, approved European orphan indications, 2019, pricing analysis, orphan drugs - price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

Key Questions Answered

  • What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?

Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Key Topics Covered:

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology

3. Executive Summary

3.1. Global Short Bowel Syndrome Market: Market Snapshot

4. Market Overview

4.1. Global Short Bowel Syndrome Market: Type Overview

4.2. Global Short Bowel Syndrome Market: Key Industry Developments

4.3. Market Dynamics

4.4. Drivers and Restraints Snapshot Analysis

4.5. Drivers

4.6. Restraints

4.7. Opportunities

4.8. Global Short Bowel Syndrome Market Revenue Projections (US$ Mn), 2017-2027

5. Key Insights

5.1. Drivers & Restraints Impact Analysis

5.2. Value Chain Analysis

5.3. Short Bowel Syndrome: Disease Overview

5.4. Short Bowel Syndrome: Epidemiology

5.5. Rare Diseases Prevalence

5.6. Overview of Clinical Trials for Short Bowel Syndrome

5.7. Qualitative Analysis of GLP-2 Product

5.8. Research & Development Cost Analysis

5.9. Impact Analysis of Clinical Trials Cost on Orphan Drugs

5.10. Cost Analysis of Therapies using Orphan Drugs

5.11. Approved U.S. Orphan Indications, 1983-2015

5.12. Approved European Orphan Indications, 2019

5.13. Pricing Analysis

5.14. Orphan Drugs - Price Volume Analysis

5.15. Justifications for the High Cost of Gattex & Teduglutide

5.16. Regulations Scenario Assessment

5.17. Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia

5.18. Impact Analysis of Regulatory Scenario Assessment

5.19. Comparative Analysis of Orphan Drug Policies

5.20. Orphan Drug Manufacturing Companies - Acquisitions Timeline

5.21. Orphan Drugs Market- Swot Analysis

6. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.1. Introduction

6.2. Global Short Bowel Syndrome Market Value and Forecast, by Drug Class

6.2.1. Glucagon-like Peptide-2 (GLP-2)

6.2.2. Growth Hormone

6.2.3. Glutamine

6.2.4. Others

6.3. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.4. Global Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

7. Global Short Bowel Syndrome Market Analysis, by Region

7.1. Global Short Bowel Syndrome Market Value and Forecast, by Region, 2017-2027

7.1.1. North America

7.1.2. Europe

7.1.3. Japan

7.1.4. Rest of the World

7.2. Global Short Bowel Syndrome Market Analysis, by Region

7.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region

8. North America Short Bowel Syndrome Market Analysis

9. Europe Short Bowel Syndrome Market Analysis

10. Japan Short Bowel Syndrome Market Analysis

11. Rest of the World Short Bowel Syndrome Market Analysis

12. Competitive Landscape

12.1. Company Profiles

12.1.1. Shire plc (Takeda Pharmaceutical Company Limited)

12.1.2. Zealand Pharma A/S

12.1.3. Sancilio & Company, Inc.

12.1.4. OxThera

12.1.5. Nutrinia Ltd

12.1.6. Ardelyx, Inc.

12.1.7. Emmaus Life Sciences, Inc.

12.1.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)

12.1.9. Merck KGaA

12.1.10. Naia Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/wvh0y6

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900